CLS and University of Texas Medical Branch sign Letter of Intent

Clinical Laserthermia Systems (CLS) (publ), which develops and markets Interstitial Laser Thermo Therapy (imILTCLS), a polyclinical, heat-induced cancer immunotherapy, and the Department of Radiology at University of Texas Medical Branch (UTMB) have signed a Letter of Intent. The agreement is aimed at formalizing the collaborative project that the parties have decided to carry out, following extensive discussions, and which is intended to lead to routine treatment of cancer patients.

The initial stage of the collaboration will involve a minor adaptation of CLS’s disposable materials and subsequent clinical evaluation through treatment of a limited number of patients.

“We have engaged in discussions for some time concerning the new treatment possibilities CLS and UTMB have identified in our products in interventional oncology. It is very encouraging that we have now established a collaboration, which gives us access to UTMB’s experience, resources and patient base,” says Dan Mogren, Chief Commercial Officer at CLS. “In its capacity as a center of health science and medical education, UTMB belongs to an extensive network of hospitals in the United States, which is naturally also valuable to us.”

More information about the University of Texas Medical Branch: www.utmb.edu

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Aktietorget under the stock symbol CLS B. More information is available on the Company's website www.clinicallaser.se